VUKOTIC, Ranka
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.824
AS - Asia 1.996
EU - Europa 1.580
SA - Sud America 264
AF - Africa 67
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.740
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.747
SG - Singapore 639
CN - Cina 444
PL - Polonia 324
HK - Hong Kong 302
GB - Regno Unito 292
VN - Vietnam 281
SE - Svezia 195
BR - Brasile 189
FI - Finlandia 174
IT - Italia 142
RU - Federazione Russa 102
DE - Germania 100
KR - Corea 61
IN - India 43
BG - Bulgaria 39
CA - Canada 36
UA - Ucraina 34
BD - Bangladesh 32
ES - Italia 31
FR - Francia 29
TR - Turchia 29
AR - Argentina 26
ID - Indonesia 26
JP - Giappone 26
NL - Olanda 24
ZA - Sudafrica 24
AE - Emirati Arabi Uniti 20
IQ - Iraq 18
MX - Messico 17
CZ - Repubblica Ceca 15
AT - Austria 13
CO - Colombia 11
VE - Venezuela 11
LT - Lituania 10
MA - Marocco 10
PH - Filippine 9
RO - Romania 9
CL - Cile 8
EG - Egitto 8
MY - Malesia 8
PK - Pakistan 8
DZ - Algeria 7
ET - Etiopia 7
PE - Perù 7
CR - Costa Rica 6
DO - Repubblica Dominicana 6
SA - Arabia Saudita 6
AL - Albania 5
AU - Australia 5
BE - Belgio 5
CH - Svizzera 5
GR - Grecia 5
IE - Irlanda 5
IL - Israele 5
PY - Paraguay 5
TN - Tunisia 5
UZ - Uzbekistan 5
JO - Giordania 4
PR - Porto Rico 4
QA - Qatar 4
A2 - ???statistics.table.value.countryCode.A2??? 3
EE - Estonia 3
GE - Georgia 3
KH - Cambogia 3
KZ - Kazakistan 3
RS - Serbia 3
TH - Thailandia 3
UY - Uruguay 3
BO - Bolivia 2
EC - Ecuador 2
GT - Guatemala 2
HR - Croazia 2
IR - Iran 2
MT - Malta 2
NP - Nepal 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TW - Taiwan 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CU - Cuba 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GD - Grenada 1
HN - Honduras 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MC - Monaco 1
MK - Macedonia 1
Totale 7.733
Salva come PNG Salva come JPEG
Città #
Santa Clara 527
Singapore 434
Ashburn 406
Warsaw 319
Fairfield 313
Chandler 302
Hong Kong 298
Helsinki 168
Nyköping 157
Houston 155
Woodbridge 124
Wilmington 112
Cambridge 108
Southend 104
San Jose 103
Beijing 100
London 98
Seattle 97
Ho Chi Minh City 88
Chicago 84
Los Angeles 81
Hanoi 73
New York 61
Council Bluffs 60
The Dalles 54
Seoul 53
San Diego 52
Hefei 51
Ann Arbor 49
Moscow 46
Dearborn 44
Salt Lake City 44
Princeton 41
Sofia 38
Orem 33
Jacksonville 31
Modena 30
Shanghai 28
São Paulo 26
Tokyo 23
Da Nang 20
Frankfurt am Main 20
Jakarta 20
Buffalo 19
Palma 18
Haiphong 16
Jersey City 16
Redwood City 16
Dallas 15
Tampa 14
Izmir 13
Brno 12
Vancouver 12
Brooklyn 11
Elk Grove Village 11
Johannesburg 11
Wuhan 11
Baghdad 10
Belo Horizonte 10
Bremen 10
Guangzhou 10
Nanjing 10
Redondo Beach 10
Sterling 10
Berlin 9
Bologna 9
Chennai 9
Falls Church 9
Grafing 9
Kilburn 9
Toronto 9
Augusta 8
Cairo 8
Chiswick 8
Denver 8
Eugene 8
Montreal 8
Vienna 8
Addis Ababa 7
Amsterdam 7
Groningen 7
Istanbul 7
Lauterbourg 7
Milan 7
Poplar 7
Brasília 6
Campinas 6
Dubai 6
Düsseldorf 6
Hounslow 6
Norwalk 6
Rijnsburg 6
Riverside 6
Rosario 6
Southend-on-Sea 6
Stanford 6
West Jordan 6
Athens 5
Atlanta 5
Brussels 5
Totale 5.595
Salva come PNG Salva come JPEG
Nome #
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF) 614
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis 403
ANTICOAGULANT THERAPY IS SAFE AND EFFECTIVE IN PREVENTING PORTAL VEIN THROMBOSIS (PVT) IN ADVANCED CIRRHOTIC PATIENTS: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 386
Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C 373
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 296
ENOXAPARIN PREVENTS PORTAL VEIN THROMBOSIS (PVT) AND DECOMPENSATION IN ADVANCED CIRRHOTIC PATIENTS: FINAL REPORT OF A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 295
Reproductive status is associated with the severity of fibrosis in women with hepatitis C. 289
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study 244
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 222
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 202
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 198
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 198
Clinical and serological profile of primary biliary cirrhosis in men 195
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 180
Familial intrahepatic cholestasis: New and wide perspectives 179
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 177
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 172
De novo autoimmune hepatitis in liver transplant: State-of-the-art review 159
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 159
The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series 156
Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B 156
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D 156
Bone marrow derived stem cells for the treatment of end-stage liver disease 150
Hepatitis C Virus Core Antigen (HCVAg): An affordable assay to monitor the efficacy of treatment in DAAs era 148
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B 145
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 143
Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group 140
Hepatitis B virus and immune response 136
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation 133
Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older 125
Impact of psychosocial status on liver transplant process 123
Insights into cancer severity from biomolecular interaction mechanisms 117
Hepatitis C virus eradication in the elderly: The challenge worth a long-life elixir? 115
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin 114
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study 113
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 113
The increase of Ribavirin dose improves sustained virological response in HCV-Genotype 1 patients with a partial response to PEG-Interferon and Ribavirin. 112
Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholi fatty liver disease: an Italian community-based population study 112
Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort 109
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 105
Managing HCV treatment failure and the potential of resistance testing in informing second-line therapy options 104
Diagnostic Performance of PIVKA-II in Italian Patients with Hepatocellular Carcinoma 42
Totale 7.808
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021170 0 0 0 0 0 0 0 0 0 24 127 19
2021/2022726 58 30 40 40 16 51 23 87 83 77 123 98
2022/2023746 108 105 69 78 74 114 11 67 81 4 21 14
2023/2024455 21 25 27 70 102 21 43 47 5 6 21 67
2024/20251.530 47 12 4 121 353 241 67 121 171 102 118 173
2025/20263.141 188 63 165 322 535 547 406 191 389 335 0 0
Totale 7.808